TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE C

NCT06344052: To Assess the Safety and Efficacy of SP-002 with Vismodegib for the Treatment of Locally Advanced Basal Cell Carcinoma

Sponsor: Stamford Pharmaceuticals, Inc. · Phase: PHASE2 · Area: ONCOLOGY · Target Enrollment: 80 pts

Competing Trials Overlap

8 Active Trials

Excess Burn Exposure

$2,032,800

Rescue Site Savings

+$1,339,800

Unlock Full NCT06344052 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT06344052 Rescue Dossier →